Indian Pharmaceuticals Say Antibiotic API Prices Could Increase By Half
This article was originally published in PharmAsia News
Indian drug makers say the active pharmaceutical ingredients for antibiotics could cost as much as 50 percent more as a result of a government anti-dumping response
You may also be interested in...
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.
After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.